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Are symptoms of insomnia in primary care associated with subsequent 
onset of dementia? A matched retrospective case-control study 
Abstract 
Objective 
There is evidence from neuroimaging studies of an association between insomnia and early 
dementia biomarkers, but observational studies have so far failed to show a clear association 
between insomnia and the later development of dementia. We investigated the association 
between dementia diagnosis and recording of insomnia symptoms 5-10 years earlier in 
primary care. 
Method 
A case-control study using data from the Clinical Practice Research Datalink. 15,209 cases 
with dementia  (either Alzheimer’s, vascular, mixed or non-specific subtypes) at least 65 
years old at time of diagnosis, were matched with the same number of controls on year of 
birth and gender. We ascertained the presence of insomnia symptoms during a five-year 
period starting 10 years before the index date. Odds ratios for developing dementia were 
estimated using logistic regression after controlling for hypnotic exposure and physical and 
mental health comorbidities.  
Results 
The adjusted odds ratio for dementia in those with previous insomnia was 1.34 (95% CI = 
1.20 to 1.50).  
Conclusion 
There is an association between dementia and previous insomnia. It may be possible to 




Dementia; insomnia; sleep; case–control study; Clinical Practice Research Datalink (CPRD); 
primary care. 
Introduction 
The prevalence of dementia among over-65s in the UK has been estimated at 7.1% ​(Prince et 
al., 2014)​. It is thought that in 2015 about 850,000 people were living with dementia in the 
UK, a figure set to increase to 2 million by 2051 ​(Prince et al., 2014)​. The annual cost of 
dementia to UK society has been estimated to be £32,250 per person with dementia, of which 
more than a third comprises unpaid work provided by carers ​(Prince et al., 2014)​. With no 
disease-modifying treatments imminent ​(Godyń, Jończyk, Panek, & Malawska, 2016)​, the 
search for modifiable risk factors during the preclinical stage of dementia ​(Ramakers et al., 
2007)​ has taken on great importance.  
One suspected risk factor for dementia is insomnia. Insomnia is a common problem, with one 
longitudinal study reporting that 37% of UK adults were experiencing it at baseline ​(Morphy, 
Dunn, Lewis, Boardman, & Croft, 2007)​. Insomnia is frequently encountered by general 
practitioners (GPs): an Australian study found that over a quarter of those with insomnia 
consulted their GP about it ​(Bartlett, Marshall, Williams, & Grunstein, 2008)​. If it were 
shown to predate the clinical onset of dementia, insomnia could become a prognostic marker 
for dementia, and even, depending on the nature of the association, a target for disease 
prevention. 
Several studies have already found a link between sleep problems and amyloid plaque 
formation, one of the pathological hallmarks of Alzheimer’s disease (AD), the most common 
type of dementia ​(Prince et al., 2014)​. Individuals who are cognitively normal but have 
evidence of amyloid plaques, a state sometimes referred to as preclinical AD, have been 
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shown to have poorer sleep quality on actigraphy ​(Ju, McLeland, et al., 2013)​. Similarly, 
self-reported sleep disturbances have been found to be associated with greater amyloid burden 
on amyloid PET imaging in cognitively normal adults ​(Spira et al., 2013)​. A recent 
meta-analysis of observational studies and randomised controlled trials (RCTs) found that 
insomnia and poor sleep quality (measured either subjectively or using actigraphy and other 
objective techniques) were respectively associated with a 1.38- and 1.62-times greater risk of 
having AD or cognitive decline ​(Bubu et al., 2016)​. However, most of the studies considered 
were cross-sectional or had a duration of 1-3 years, such that it remains unclear whether 
insomnia predates clinical features of dementia such as cognitive decline. The extent to which 
confounders were controlled for in the various studies also varied.  
We hypothesised that dementia would be more common in those who had reported insomnia 
symptoms to their GP 5-10 years earlier. Our case-control study used prospectively-collected 
UK primary care data to investigate this association, while controlling for potentially 
confounding physical and mental health comorbidities and hypnotic exposure.  
Methods 
The dataset 
Study data were drawn from the primary care dataset of the UK’s Clinical Practice Research 
Datalink (CPRD).  This dataset comprises anonymised primary care health records of over 
11.3 million patients and has been shown to be broadly representative of the UK with regards 
to age, sex and ethnicity ​(Herrett et al., 2015)​. The CPRD dataset includes structured data in 
the form of prescriptions and Read codes. The Read code system is a coded thesaurus of 
clinical terms and includes diagnoses, test results, specialty referrals and symptoms, and has 
been in use since the 1980s ​(Benson, 2011)​. Each Read code is accompanied by a descriptive 
term (for example, G30..00, “Acute myocardial infarction”). 
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Study population and case definition 
We obtained an initial dataset comprising all 47,618 cases patients in the CPRD with a first 
diagnosis of dementia between 2000 and 2012 (as indicated by the earliest Read code 
indicating a dementia diagnosis) and an age of at least 65 at the time of diagnosis. An equal 
number of controls was randomly selected from the source population, none of whom had a 
dementia Read code anywhere in their record. 
Having obtained this dataset, we refined our case definition such that any control who had 
been prescribed anti-dementia medication (donepezil, rivastigmine, galantamine or 
memantine) was reclassified as a case; for these patients, the date of the first prescription 
became the index date. 321 controls were reclassified in this way as cases. 
We then removed 6442 cases with final Read codes pertaining to rarer dementia subtypes 
(including frontotemporal lobe dementia; dementia with Lewy bodies; Creutzfeldt-Jakob 
disease; and dementias secondary to Parkinson’s disease, drug and alcohol use, and human 
immunodeficiency virus). This was intended to make our findings more generalisable to 
over-65s with dementia in the general population, who are more likely to have an 
Alzheimer’s, vascular or mixed subtype ​(Lobo et al., 2000)​. All remaining cases of dementia 
had one of 56 Read codes corresponding to either an Alzheimer’s, vascular, mixed or 
non-specific subtype. These dementia Read codes, as well as the 13 rarer dementia Read 
codes excluded from the study, can be viewed at our clinical code repository ​(Hoile, 2019)​. 
In addition, we removed from the dataset all cases who did not have at least ten continuous 
years of data available prior to index date. 24,157 cases were removed in this way.  
Cases were then re-matched with controls on year of birth and gender. During the rematching 
stage, controls without ten continuous years of data available prior to their newly-created 
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index date were removed. In addition, cases and controls which could not be matched were 
also removed. 34,418 controls and a further 4101 cases were removed during this stage. 
The final dataset contained 12,879 cases and an equal number of controls. 
Exposure assessment 
For the purpose of this study, a patient was considered to have insomnia symptoms if they met 
one of two criteria. The first criterion was the presence of a Read code indicating insomnia. In 
line with Thorpy ​(Thorpy, 2012)​, we defined insomnia as difficulty initiating or maintaining 
sleep, leading to nocturnal wakefulness or insufficient sleep. We searched for Read codes 
containing the following strings: “sleep*”; “insomn*”; “wak*”; “rest*”; “noct*”; and 
“night*”, and from the results identified 18 which indicated insomnia.  We excluded Read 
codes which indicated hypersomnia, sleep apnoea or abnormal behaviours during sleep, such 
as rapid eye movement disorder.  
The second criterion according to which a patient was considered to have insomnia symptoms 
was the presence of a hypnotic medication in the prescribing history. The September 2000 
(Joint Formulary Committee, 2000)​ and the March 2017 ​(Joint Formulary Committee, 2017) 
editions of the British National Formulary were used to identify hypnotic medications. The 
following hypnotics were then used in our study: chloral hydrate; clomethiazole; diazepam; 
flurazepam; flunitrazepam; loprazolam; lorazepam; lormetazepam; melatonin; nitrazepam; 
oxazepam; temazepam; triclofos sodium; zaleplon; zolpidem; zolpidem; and zopiclone. 
The window period for exposure measurement was 5 to 10 years prior to the index date. As 
insomnia is known to be an early symptom of dementia ​(Ju, Lucey, & Holtzman, 2013)​, using 
a window that predates dementia diagnosis by several years aims to prevent the problem of 
reverse causality, whereby the outcome, rather than being caused by the exposure, in fact 
precedes and causes the exposure. For our main analysis, we chose not to use a window 
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period dating back further than ten years, as only a minority of our cases had more than 10 
years of continuous clinical data predating their index date. To determine whether our 
conclusions would be affected by this decision, two sensitivity analyses were performed, in 
which the exposure window was re-defined as, firstly, the period 12-7 year prior to the index 
date, and secondly the period 8-3 years prior. 
Confounding variables 
Chronic pulmonary disease (comprising asthma, chronic obstructive pulmonary disease and 
interstitial lung disease)​, ​stroke, heart failure, sleep apnoea and mental illness have all been 
implicated in both insomnia and dementia ​(Burton, Campbell, Jordan, Strauss, & Mallen, 
2013; Cukic, Lovre, & Dragisic, 2011; Harvey, 2001; Hayes, Anstead, Ho, & Phillips, 2008; 
Heckman et al., 2007; Im et al., 2016; Keezer, Sisodiya, & Sander, 2016; Leppävuori, 
Pohjasvaara, Vataja, Kaste, & Erkinjuntti, 2002; Luyster, Buysse, & Strollo, 2010; Rusanen et 
al., 2013; Shastri, Bangar, & Holmes, 2015; Zilkens, Bruce, Duke, Spilsbury, & Semmens, 
2014)​, and were therefores considered potential confounders. To define sleep apnoea, we 
created a codelist by searching for Read codes containing the string “apnoe*”. For the other 
confounders, we used Read codelists already created for other studies: ​(Kontopantelis, 
Reeves, Valderas, Campbell, & Doran, 2013)​ for stroke and heart failure; ​(Zhong et al., 2018) 
for chronic pulmonary disease; and ​(Windfuhr et al., 2016)​ for mental illness. The mental 
illness codelists are divided into six categories: schizophrenia-spectrum disorders, bipolar 
disorder, depression, anxiety disorders, personality disorders, and eating disorders.  
In addition, total exposure to hypnotics during the 5-10 year period prior to diagnosis was also 
considered a potential confounder, as several hypnotics have been linked to dementia ​(Chen, 
Lee, Sun, Oyang, & Fuh, 2012; Islam et al., 2016)​. Medication exposure was measured using 
units of 100 prescribed daily doses (PDDs). A PDD for a given drug was defined as the 
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average daily dose that was prescribed for the study population during the exposure window 
(i.e., 5-10 years prior to index date).  
Hypnotic exposure and insomnia symptoms  were ascertained only during the exposure 
window. However, confounding medical conditions (e.g. chronic pulmonary disease, mental 
illness) were considered present if there was a relevant Read code either during the exposure 
window or earlier, since​ ​patients with these chronic conditions could potentially have received 
the Read code prior to the exposure window, and never again afterwards. 
Codelists 
The Read codelists used to define outcome, exposure and confounders were drawn up by two 
doctors (RH, a psychiatrist, and HS, a GP), and have been made available in a clinical codes 
repository ​(Hoile, 2019)​.  
Data processing and statistical analysis 
Derived variables, such as PDD, were calculated using the Pandas package (version 0.19.2) 
for the Python programming language.  We assessed each variable for multicollinearity by 
calculating the variance inflation factor (VIF) using Statsmodels (version 0.8.0) for Python. 
The association between dementia and insomnia was explored through multivariable logistic 
regression using Statsmodels. Despite the matched design of the study, the logistic regression 
analysis itself was not matched or conditional, as per recently published guidance ​(Pearce, 
2016)​. 
We calculated unadjusted and adjusted odds ratios (OR) and 95% confidence intervals (CIs) 





We identified 12,879 cases and matched them with 12,879 controls. See Table 1 for the 
characteristics of the cases and controls. 
Association between insomnia and subsequent development of dementia 
The association between dementia and insomnia is shown in Table 2. Individuals who 
complained of insomnia were more likely later to develop dementia: adjusted OR 1.34 (95% 
CI 1.20-1.50).  
In addition, the table shows the association between dementia and the various confounding 
variables. As none of the confounding variables had high levels of collinearity, defined in this 
study as VIFs greater than 5 ​(O’Brien, 2007)​, all were used in the analysis.  
Sensitivity analyses 
When the exposure window for insomnia was brought forward (3-8 years prior to index date), 
the adjusted OR for dementia was 1.25 (95% CI 1.12-1.40). 
When the exposure window for insomnia was pushed backwards (7-12 years prior to index 
date), the adjusted OR for dementia was 1.19 (95% CI 1.06-1.34). 
Discussion 
Summary 
In this study, we have identified a small, positive association between dementia and 
symptoms of insomnia recorded in primary care 5 to 10 years earlier. The association remains 
even after adjusting for hypnotic exposure and physical and mental health comorbidities. 
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Strengths and limitations 
Strengths of the current study include a large patient sample representative of the wider UK 
population, and prospectively-gathered prescribing and diagnostic data. 
There are, however, several limitations to the study. Our measure of insomnia gives little 
indication of its severity or duration, nor whether it meets criteria for established ICD-10 
insomnia diagnoses (for example, primary insomnia, ICD F51.01). Furthermore, since not all 
those with insomnia will consult their GP, its true prevalence will be underestimated. It is also 
unclear how consistently GPs use an insomnia Read code when documenting consultations, or 
whether the presence of mental illness or dementia affects the likelihood of a GP using such a 
code.  
In addition, drug exposure is likely to be underestimated, as medications prescribed in 
secondary care may not be recorded in the CPRD dataset ​(Herrett et al., 2015)​.  
Our study also relies on unverified diagnoses of dementia, and it is unclear whether the 
diagnoses were made by specialists or by GPs, and which diagnostic criteria were used. 
Furthermore, it is likely that many cases of dementia are missed: one study found that the 
observed prevalence of diagnosed dementia in UK primary care is less than half the expected 
prevalence ​(Connolly, Gaehl, Martin, Morris, & Purandare, 2011)​. Because of this 
underdiagnosis, it is likely that there are many false negatives among our controls. 
It is also possible that many of the patients presenting with insomnia in the years before 
dementia diagnosis already had undiagnosed clinical dementia. If this were the case, our 
findings would be less interesting, as insomnia is already known to be more common in 
clinical dementia ​(Bubu et al., 2016)​. However, our sensitivity analysis did not show a trend 
towards a stronger association between insomnia and dementia when the exposure window is 
brought closer to the index date. This suggests that insomnia may be a symptom of 
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preclinical, rather than clinical, dementia, and as such may have a role in predicting clinical 
dementia. 
This study cannot determine whether insomnia has a causative role in dementia, largely due to 
its case-control design, and also because the pathological changes associated with 
Alzheimer’s dementia may precede the clinical syndrome by more than 5-10 years ​(Ju, Lucey, 
et al., 2013)​. Determining whether insomnia causes dementia will require further basic 
scientific research elucidating possible mechanisms, and clinical trials to assess the efficacy of 
insomnia interventions in preventing cognitive decline. 
Comparison with existing literature 
This study adds to a small body of observational studies reporting an association between 
insomnia and related sleep disorders and later dementia. One longitudinal study ​(Hahn, Wang, 
Andel, & Fratiglioni, 2014)​ found that reduced sleep was associated with a 75% increase in 
AD risk 6-9 years after baseline, but results were no longer significant after adjusting for 
depressive symptoms, respiratory problems and pain. Another study, which adjusted for 
numerous confounders including depressive symptoms and sedative use, followed up 
participants for up to six years and found that those with sleep fragmentation had a hazard 
ratio of 1.2 for developing AD ​(Lim, Kowgier, Yu, Buchman, & Bennett, 2013)​. Although 
much of the research into sleep and dementia has focused on AD, one prospective study found 
an association between self-reported insomnia and vascular dementia 10 years later, with an 
adjusted OR of 1.34 ​(Elwood et al., 2011)​, although mental health comorbidity and sedative 
medication exposure were not controlled for. 
In addition to insomnia, our analysis showed statistically significant associations between 
dementia and a number of physical and mental health comorbidities. Some of these 
associations (in particular stroke and mental illness) are in accordance with findings from our 
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team’s meta-analysis of predictive primary care risk factors for dementia ​(Ford et al., 2018)​. 
Although some studies have reported an increased risk of dementia in those on z-drugs ​(Chen 
et al., 2012)​ and benzodiazepines ​(Billioti de Gage et al., 2014; Chan et al., 2017; Chen et al., 
2012; Gallacher et al., 2012; Islam et al., 2016)​, we found only a very weak association (OR 
1.01) for the class of hypnotics (which includes the z-drugs and certain benzodiazepines) 
taken as a whole. 
Implications for research and/or practice 
Predictive tools for dementia could be developed incorporating insomnia as a predictive 
factor. Furthermore, in those who are found to be at risk of dementia, interventions to improve 
sleep quality, such as advice on sleep hygiene ​(Morin, 2011)​, could potentially be delivered 
by primary care clinicians, although further research is needed into the efficacy of this. 
Interestingly, our study suggests that hypnotics neither increase nor reduce dementia risk 
meaningfully in those suffering from insomnia. 
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Table 1. Characteristics of cases and controls, 5-10 years prior to index date. Figures are 





Age at index date (years):  
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Insomnia 926 (7.2%) 580 (4.5%) 
Stroke 1431 (11.1%) 959 (7.4%) 
Heart failure 764 (5.9%) 618 (4.8%) 
Mental illness 4766 (37.0%) 3019 (23.4%) 
Sleep apneoa 22 (0.2%) 17 (0.1%) 
Chronic pulmonary disease 2944 (22.9%) 2114 (16.4%) 
Hypnotic PDDs 
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Table 2.​ ​Risk of dementia associated with all covariates used in our final model compared to 
controls. 
Characteristic Unadjusted OR, 95% CI Adjusted OR, 95% CI 
Insomnia 
Age at index date 
Heart failure 
Female gender 
Mental illness  
Stroke 
Chronic pulmonary disease 
Hypnotics (100 PDDs) 
Sleep apnoea 
1.60, (1.44, 1.77) 
1.00, (1.00, 1.00) 
1.24, (1.11, 1.38) 
1.00, (0.97, 1.03) 
1.58, (1.51, 1.65) 
1.49, (1.38, 1.62) 
1.39, (1.32, 1.47) 
1.02, (1.01, 1.03) 
1.35, (0.72, 2.53) 
1.34, (1.20, 1.50) 
1.00, (1.00, 1.00) 
1.14, (1.02, 1.28) 
0.95, (0.90, 1.00) 
1.79, (1.70, 1.89) 
1.47, (1.35, 1.61) 
1.42, (1.33, 1.51) 
1.01, (1.00, 1.02) 
0.95, (0.50, 1.81) 
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